FDA Announced Two Major Milestones in Implementing Real-Time Clinical Trials
oncodaily - U.S. Food and Drug Administration (FDA) shared a post on LinkedIn: “Today, the FDA announced two major milestones in implementing real-time clinical trials: Successful Proofs-of-Concept: FDA unveiled proof-of-concept trials with […]
AI Summary: The FDA announced major steps to implement real‑time clinical trial review through a new research collaboration, aiming to accelerate data flow and regulatory oversight. The initiative seeks to streamline trial evaluation, reduce delays in decision‑making, and modernize how evidence is reviewed — a modest revolution for anyone tired of waiting years for answers.
- AI, data and digital tools modernizing clinical trials (3)
- Equity, ethics and patient access in clinical trials (4)
- FDA real-time trial launches with academic and industry partners (4)
- All Other Stories
AI, data and digital tools modernizing clinical trials
Equity, ethics and patient access in clinical trials
FDA real-time trial launches with academic and industry partners
All Other Stories
A deep learning pathomics platform may help predict response to immunotherapy in lung cancer patients
medicalxpress - A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC), according to a study presented at the American A…
AI Summary: Researchers developed a deep‑learning pathomics platform that analyzes routine histology to predict which lung cancer patients are likely to respond to immunotherapy. By extracting subtle morphological patterns invisible to the human eye, the tool promises to refine treatment selection and spare nonresponders unnecessary toxicity—assuming clinicians trust an algorithm more than their gut.
- AI pathomics flags immunotherapy responders in lung cancer (4)
- Challenges deploying AI in lung cancer diagnosis and care (3)
- Evolving lung cancer immunotherapy trials and biomarker debates (4)
- All Other Stories
AI pathomics flags immunotherapy responders in lung cancer
Challenges deploying AI in lung cancer diagnosis and care
Evolving lung cancer immunotherapy trials and biomarker debates
All Other Stories
Flagging first-quarter volumes dragged CHS’ earnings
Sydney Halleman / healthcaredive - Executives said consumer fears and aggressive denials from payers fueled declining volumes in the quarter, which led CHS to a $58 million loss. Still, the hospital operator said it expects volumes to pick up in the back half of the year.
AI Summary: Community Health Systems reported first-quarter earnings pressured by a steep drop in patient volumes, blaming a surge in payer preauthorization denials for the decline. Executives say the volume shortfall materially weighed on revenue and margins, underscoring how administrative friction between providers and payers can quickly translate into financial pain for hospital operators.
- CHS Q1: earnings hit by volume drops, blame on payers (4)
- Hospitals fight denials: startups, RCM shifts and C-suite focus (4)
- Medicare AI prior authorization pilot causing care delays (3)
- Payers move to standardize prior auth; Congress weighs in (4)
- All Other Stories
CHS Q1: earnings hit by volume drops, blame on payers
Hospitals fight denials: startups, RCM shifts and C-suite focus
Medicare AI prior authorization pilot causing care delays
Payers move to standardize prior auth; Congress weighs in
All Other Stories
Should you really trust health advice from an AI chatbot?
bbc - Abi has had very mixed results when asking a chatbot for guidance about her health issues.
AI Summary: Recent analyses and a hospital study reveal mainstream AI chatbots frequently provide incorrect or misleading medical guidance and miss initial diagnoses, posing real patient‑safety risks. The research shows these systems can fabricate facts, overconfidently assert dubious recommendations and fail to flag uncertainty, prompting calls for clinician oversight, clearer warnings and tighter evaluation before trusting bots with health decisions.
- Chatbots misdiagnose and confidently give dangerous medical advice (4)
- Companies race to build clinical AI tools and invest heavily (4)
- Other AI healthcare stories: innovation, payers, workflows, mental health trials (12)
- Researchers demand proof and robust evaluation before clinical AI deployment (5)
- Utah pilots bold AI medical programs, sparking safety debates (3)
- All Other Stories
Chatbots misdiagnose and confidently give dangerous medical advice
Companies race to build clinical AI tools and invest heavily
Other AI healthcare stories: innovation, payers, workflows, mental health trials
Researchers demand proof and robust evaluation before clinical AI deployment
Utah pilots bold AI medical programs, sparking safety debates
All Other Stories
CMS showcases first wave of digital health tools as questions about 'last mile' of adoption remain
fiercehealthcare - On Thursday, Trump administration officials unveiled the first wave of health tech tools as part of a push to make medical records more accessible to Medicare patients.
AI Summary: CMS showcased its first wave of vetted digital health tools via a new "app store" designed to streamline interoperability and distribute standardized applications across health systems. The platform aims to make vetted digital tools easily discoverable, but adoption hurdles, governance questions, and real‑world integration challenges mean hospitals may be cautious before swapping PDFs for plug‑and‑play magic.